Hospital Angelina Caron Joins Clinerion’s Patient Network
Hospital Angelina Caron, of Campina Grande do Sul, Paraná, is the latest Brazilian hospital to join Clinerion’s network of partner hospitals on its Patient Network Explorer platform. Hospital Angelina Caron has nearly one million patients and specializes in cardiology, ophthalmology, pediatrics and neonatology, gynecology and obstetrics, orthopedics, transplants, obesity and digestive system, oncology, neurology, cardiology, nephrology, vascular and endovascular surgery. The hospital has run 10 international trials per year for the past five years.
Clinerion’s Patient Network Explorer helps partner hospitals be visible to pharmaceutical companies seeking suitable patients and sites for their clinical trials. Leveraging patient medical data, queries based on trial protocols may be sent to partner hospitals to assess the count of eligible patients in their electronic health records. All patient data is de-identified and remains under the control of the hospital and inside its IT infrastructure. However, Clinerion’s patented technology also enables authorized trial staff at the hospital to re-identify the patient for the purpose of trial recruitment, while maintaining strict personal data privacy standards.
“With the Clinerion database system, there will be a great progress in research at our center, facilitating patient selection and increasing our effectiveness. Today, a database and facilitating access to information are fundamental to the evolution of research”, says Dalton B. Precoma MD, PhD, cardiologist of Hospital Angelina Caron.
“We are so pleased that our patient coverage in Brazil is expanding by leaps and bounds,” says Ian Rentsch, CEO of Clinerion. “It shows that the benefits of visibility to pharmaceutical trial sponsors that we offer to hospitals running international clinical trials are well understood and accepted.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
